Valeritas - About the company
Valeritas is an acquired company based in Bridgewater (United States), founded in 2003. It operates as a Developer of wearable insulin patch pumps for insulin delivery through the skin. Valeritas has raised $231M in funding from Welsh, Carson, Anderson & Stowe. The company has 93 active competitors, including 31 funded and 16 that have exited. Its top competitors include companies like Vaxxas, scPharmaceuticals and CeQur.
Company Details
Developer of wearable insulin patch pumps for insulin delivery through the skin. It offers holds one day's supply of fast-acting insulin and releases it at a continuous preset basal rate and on-demand bolus dosing at mealtimes. Its pump is not programmable and does not use electricity. Its devices are available at a preset basal rate to deliver diverse amounts of insulin in a day and on-demand bolus dosing.
- Website
- www.valeritas.com/
- Social
Key Metrics
Founded Year
2003
Location
Bridgewater, United States
Stage
Acquired
Total Funding
$231M in 6 rounds
Latest Funding Round
Investors
Ranked
6th among 93 active competitors
Employee Count
51 - 200 as on Mar 01, 2026
Exit Details
Acquired by Zealand Pharma (Feb 10, 2020)
Valeritas's acquisition details
Valeritas got acquired by Zealand Pharma on Feb 10, 2020 at an acquisition amount of $*****.
Click here to take a look at Valeritas's acquisition in detail
Sign up to download Valeritas' company profile
Valeritas's funding and investors
Valeritas has raised a total funding of $231M over 6 rounds. Its first funding round was on Nov 10, 2008. Its latest funding round was a Post IPO round on May 04, 2016 for $*****. 2 investors participated in its latest round. Valeritas has 14 institutional investors.
Here is the list of recent funding rounds of Valeritas:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 04, 2016 | 3482052 | Post IPO | 9487207 | 9196536 | 3494807 | 3333079 |
Jul 07, 2014 | 4868368 | Series D | 1315953 | 1733329 | 1262500 | 5237486 |
Jun 04, 2013 | 5191795 | Conventional Debt | 2817794 | 4351829 | 5322710 |
Access funding benchmarks and valuations. Sign up today!View details of Valeritas's funding rounds and investors
Valeritas' founders and board of directors
Founder? Claim ProfileValeritas' employee count trend
Valeritas has 51 - 200 employees as of Mar 26. Here is Valeritas's employee count trend over the years:
Uncover Valeritas' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Valeritas's Competitors and alternates
Top competitors of Valeritas include Vaxxas, scPharmaceuticals and CeQur. Here is the list of Top 10 competitors of Valeritas, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of a needle-free patch technology for vaccine delivery applications | $91.2M | 65/100 | ||
2nd | scPharmaceuticals 2013, Lexington (United States), Acquired | Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure | $78.7M | 60/100 | |
3rd | CeQur 2008, Horw (Switzerland), Series E | Developer of wearable insulin delivery patch | $492M | 58/100 | |
4th |  BioSapien 2018, New York City (United States), Seed | Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents | $10.6M | 58/100 | |
5th |  Hero Patch 2019, Boston (United States), Series A | Developer of antibodies or small molecules for drug delivery | $20.5M | 54/100 | |
6th | Valeritas 2003, Bridgewater (United States), Acquired | Developer of wearable insulin patch pumps for insulin delivery through the skin | $231M | 46/100 | |
7th | Starton 2017, New York City (United States), Seed | Developer of drug delivery solution and drugs for treating oncology | $9.29M | 52/100 | |
8th |  Scilex Holding 2019, Palo Alto (United States), Public | Developer of non-opioid therapies for acute and chronic pain | - | 52/100 | |
9th |  Corsair Phama 2014, San Francisco (United States), Series B | Developer of drugs for the treatemnt of cardiac diseases | $23M | 51/100 | |
10th | EoFlow 2011, Seongnam-si (South Korea), Acquired | Developer of a wearable disposable insulin patch for diabetes patients | - | 48/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Valeritas's competitors? Click here to see the top ones
Valeritas's Investments and acquisitions
Valeritas has made no investments or acquisitions yet.
Reports related to Valeritas
Here is the latest report on Valeritas's geography:
News related to Valeritas
Filter this list•
Zealand Pharma completes the acquisition of ValeritasGlobeNewswire•Apr 02, 2020•Zealand Pharma, Valeritas
•
Valeritas sells business for $23M to Danish biotech firmBee Star•Mar 23, 2020•Valeritas, Zealand Pharma
•
Valeritas receives court approval of sale of business to Zealand PharmaPoandpo•Mar 21, 2020•Valeritas
•
Zealand Pharma announces bid to acquire ValeritasGlobeNewswire•Feb 10, 2020•Zealand Pharma, Valeritas,
•
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Valeritas
Explore our recently published companies
- Autocal - Thane based, 2002 founded, Funding Raised company
- Indo Amines - Thane based, 1994 founded, Public company
- Taro International - Haifa based, 1992 founded, Unfunded company
- SmartCart AI - San Francisco based, Unfunded company
- 365 Retail Markets - London based, 2008 founded, Unfunded company
- Bishop Paiute Development Corporation - Bishop based, 2009 founded, Funding Raised company
